[{"orgOrder":0,"company":"Xencor","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Cabazitaxel","moa":"||PDCD1","graph1":"Oncology","graph2":"Phase II","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Xencor \/ Leerink Partners"},{"orgOrder":0,"company":"Xencor","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Cabazitaxel","moa":"||PDCD1","graph1":"Oncology","graph2":"Phase II","graph3":"Xencor","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Xencor \/ Leerink Partners"},{"orgOrder":0,"company":"Xencor","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Public Offering","leadProduct":"Cabazitaxel","moa":"||PDCD1","graph1":"Oncology","graph2":"Phase II","graph3":"Xencor","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Xencor \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Xencor \/ Leerink Partners"},{"orgOrder":0,"company":"Ever Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"||Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Undisclosed"},{"orgOrder":0,"company":"AIO-Studien-gGmbH","sponsor":"ClinAssess | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"AIO-Studien-gGmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AIO-Studien-gGmbH \/ ClinAssess | Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"AIO-Studien-gGmbH \/ ClinAssess | Sanofi"},{"orgOrder":0,"company":"Jules Bordet Institute","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Jules Bordet Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jules Bordet Institute \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Jules Bordet Institute \/ Sanofi"},{"orgOrder":0,"company":"Vejle Hospital","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Vejle Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vejle Hospital \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Vejle Hospital \/ Sanofi"},{"orgOrder":0,"company":"UNICANCER","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"UNICANCER","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UNICANCER \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"UNICANCER \/ Sanofi"},{"orgOrder":0,"company":"Hellenic Cooperative Oncology Group","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Hellenic Cooperative Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hellenic Cooperative Oncology Group \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Hellenic Cooperative Oncology Group \/ Sanofi"},{"orgOrder":0,"company":"Hellenic Oncology Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Hellenic Oncology Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hellenic Oncology Research Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hellenic Oncology Research Group \/ Undisclosed"},{"orgOrder":0,"company":"Hellenic Cooperative Oncology Group","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GREECE","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Hellenic Cooperative Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hellenic Cooperative Oncology Group \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Hellenic Cooperative Oncology Group \/ Sanofi"},{"orgOrder":0,"company":"Akershus University Hospital","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Akershus University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akershus University Hospital \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Akershus University Hospital \/ Sanofi"},{"orgOrder":0,"company":"Spanish Oncology Genito-Urinary Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Spanish Oncology Genito-Urinary Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spanish Oncology Genito-Urinary Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spanish Oncology Genito-Urinary Group \/ Undisclosed"},{"orgOrder":0,"company":"University Hospitals Bristol and Weston NHS Foundation Trust","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"University Hospitals Bristol and Weston NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospitals Bristol and Weston NHS Foundation Trust \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"University Hospitals Bristol and Weston NHS Foundation Trust \/ Sanofi"},{"orgOrder":0,"company":"University Hospitals Bristol and Weston NHS Foundation Trust","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"University Hospitals Bristol and Weston NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospitals Bristol and Weston NHS Foundation Trust \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"University Hospitals Bristol and Weston NHS Foundation Trust \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Alabama at Birmingham \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"University of Alabama at Birmingham \/ Sanofi"},{"orgOrder":0,"company":"University of Southern California","sponsor":"National Cancer Institute | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Gastroenterology","graph2":"Phase II","graph3":"University of Southern California","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Southern California \/ National Cancer Institute | Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"University of Southern California \/ National Cancer Institute | Sanofi"},{"orgOrder":0,"company":"University of California, Davis","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"University of California, Davis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Davis \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"University of California, Davis \/ Sanofi"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"University of Colorado, Denver \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"British Columbia Cancer Agency","sponsor":"Sanofi | Ozmosis Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"British Columbia Cancer Agency","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"British Columbia Cancer Agency \/ Sanofi | Ozmosis Research","highestDevelopmentStatusID":"8","companyTruncated":"British Columbia Cancer Agency \/ Sanofi | Ozmosis Research"},{"orgOrder":0,"company":"Centre Hospitalier de l'Universite de Montreal","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Centre Hospitalier de l'Universite de Montreal","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier de l'Universite de Montreal \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Centre Hospitalier de l'Universite de Montreal \/ Sanofi"},{"orgOrder":0,"company":"Nova Scotia Cancer Centre","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Nova Scotia Cancer Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova Scotia Cancer Centre \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Nova Scotia Cancer Centre \/ Sanofi"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Medical College of Cornell University \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Weill Medical College of Cornell University \/ Sanofi"},{"orgOrder":0,"company":"Sidney Kimmel Cancer Center, Thomas Jefferson University","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Sidney Kimmel Cancer Center, Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Sanofi"},{"orgOrder":0,"company":"Sidney Kimmel Cancer Center, Thomas Jefferson University","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Sidney Kimmel Cancer Center, Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Sanofi"},{"orgOrder":0,"company":"Medical University of South Carolina","sponsor":"Peregrine Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medical University of South Carolina","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medical University of South Carolina \/ Peregrine Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Medical University of South Carolina \/ Peregrine Pharmaceuticals"},{"orgOrder":0,"company":"SCRI Development Innovations, LLC","sponsor":"Novartis Pharmaceuticals Corporation | GSK | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"SCRI Development Innovations, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCRI Development Innovations, LLC \/ Novartis Pharmaceuticals Corporation | GSK | Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"SCRI Development Innovations, LLC \/ Novartis Pharmaceuticals Corporation | GSK | Sanofi"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"AstraZeneca | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ AstraZeneca | Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ AstraZeneca | Merck & Co"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"MD Anderson Cancer Center \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"MD Anderson Cancer Center","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MD Anderson Cancer Center \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"MD Anderson Cancer Center \/ Sanofi"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Natco Pharma"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Natco Pharma"},{"orgOrder":0,"company":"Jina Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Jina Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jina Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jina Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Starpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Starpharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Starpharma \/ Undisclosed"},{"orgOrder":0,"company":"Starpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Starpharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Starpharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Starpharma \/ Undisclosed"},{"orgOrder":0,"company":"European Organisation for Research and Treatment of Cancer","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"European Organisation for Research and Treatment of Cancer","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"European Organisation for Research and Treatment of Cancer \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"European Organisation for Research and Treatment of Cancer \/ Sanofi"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Sanofi"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Krzysztof Misiukiewicz","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Krzysztof Misiukiewicz","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Krzysztof Misiukiewicz"},{"orgOrder":0,"company":"Sanofi","sponsor":"Anjali Zarkar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sanofi \/ Anjali Zarkar","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ Anjali Zarkar"},{"orgOrder":0,"company":"Sanofi","sponsor":"Guarionex J. Decastro","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Liquid, Instillation","sponsorNew":"Sanofi \/ Guarionex J. Decastro","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ Guarionex J. Decastro"},{"orgOrder":0,"company":"Sanofi","sponsor":"Jeffrey Yachnin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Jeffrey Yachnin","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Jeffrey Yachnin"},{"orgOrder":0,"company":"Sanofi","sponsor":"Gustave Roussy","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Gustave Roussy","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Gustave Roussy"},{"orgOrder":0,"company":"Sanofi","sponsor":"Rahul Aggarwal","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cabazitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Rahul Aggarwal","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Rahul Aggarwal"}]
Find Clinical Drug Pipeline Developments & Deals for Cabazitaxel
Details :
Cabazitaxel Intravenous Powder (generic for Jevtana Kit®), is a Microtubule inhibitor, available in the 60mg/1.5mL (40mg/mL) strength used fo the treatment of Prostate cancer.
Details :
Cabazitaxel intravenous powder of strength 60mg/1.5ml (40mg/ml), is an antineoplastic agent and a microtubule inhibitor used in the treatment of prostate cancer.
Details :
Cabazitaxel EVER Pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer.
Details :
Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.
Details :
Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.
Details :
Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.
Details :
Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Transitional Cell.
Details :
Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Nonseminomatous germ cell tumor.
Details :
Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.
Details :
Cabazitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Reset All
